In the United States, 1 in 6 men who have sex with men (MSM), including 1 in 2 Black, 1 in 4 Latinx and 1 in 11 white MSM, will be diagnosed with HIV in their lifetime. The numbers among transgender women (TGW) are equally concerning; with an estimate of 14% living with HIV, the majority of whom are Black or Latinx New approaches to HIV prevention, including new options for HIV pre-exposure prophylaxis (PrEP) are needed. The PURPOSE 2 study aims to see if a twice yearly injection for HIV prevention is safe and effective.

Interested in learning more about twice a year medication for PrEP?

You may be eligible for a study testing an investigational injectable PrEP medication given twice a year if:

Contact us: 310-709-1594